The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical utility of neurocognitive function (NCF), quality of life (QOL), and symptom assessment as prognostic factors for survival and measures of treatment effects on RTOG 0525.
T. S. Armstrong
Honoraria - Merck
Research Funding - Genentech; Merck
J. S. Wefel
Research Funding - Schering-Plough
M. Wang
No relevant relationships to disclose
M. Won
No relevant relationships to disclose
A. Bottomley
No relevant relationships to disclose
T. R. Mendoza
No relevant relationships to disclose
C. Coens
No relevant relationships to disclose
M. Werner-Wasik
No relevant relationships to disclose
D. Brachman
No relevant relationships to disclose
A. K. Choucair
No relevant relationships to disclose
M. R. Gilbert
Consultant or Advisory Role - Genentech; Sigma-Tau
Honoraria - Genentech; Merck; Sigma-Tau
Research Funding - Genentech; Merck